3-(4-Benzylpiperidin-1-ium-1-yl)propane-1-sulfonate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(4-Benzylpiperidin-1-ium-1-yl)propane-1-sulfonate
• 化学式: C15H23NO3S
• 分子量: 297.4
• InChiKey: GAZPWOBEZTYCBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  70
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Subtype-selective NMDA receptor ligands and the use thereof
  申请人：——

  公开号：US20010051633A1

  公开（公告）日：2001-12-13

  The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

  本发明涉及亚型选择性NMDA受体配体及其用于治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失，以及治疗包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病和唐氏综合症在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑，精神病，惊厥，氨基糖苷类抗生素引起的听力损失，偏头痛，慢性疼痛，帕金森病，青光眼，巨细胞病毒性视网膜炎，尿失禁，阿片类耐受或戒断，并诱导麻醉，以及增强认知能力。
• Methods and compositions for treating amyloid-related diseases
  申请人：Kong Xianqi

  公开号：US20070010573A1

  公开（公告）日：2007-01-11

  Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

  描述了用于治疗或预防与淀粉样蛋白相关的疾病的方法、化合物、制药组合物和试剂盒。
• Compositions and methods for treating amyloidosis
  申请人：Szarek Walter

  公开号：US20090099100A1

  公开（公告）日：2009-04-16

  Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described. Amyloid aggregation is modulated by the administration to a subject of an effective amount of a therapeutic compound of the formula or a pharmaceutically acceptable salt or ester, such that modulation of amyloid aggregation occurs. R 1 and R 2 are each independently a hydrogen atom or a substituted or unsubstituted aliphatic or aryl group. Z and Q are each independently a carbonyl (C═O), thiocarbonyl (C═S), sulfonyl (SO 2 ), or sulfoxide (S═O) group. “k” and “m” are 0 or 1, provided when k is 1, R 1 is not a hydrogen atom, and when m is 1, R 2 is not a hydrogen atom. In an embodiment, at least one of k or m must equal 1. “p” and “s” are each independently positive integers selected such that the biodistribution of the therapeutic compound for an intended target site is not prevented while maintaining activity of the therapeutic compound. T is a linking group and Y is a group of the formula -A X wherein A is an anionic group at physiological pH, and X is a cationic group.

  本文描述了用于调节主体中淀粉样聚集物的治疗化合物和方法，无论其临床设置如何。通过向主体投予公式中的治疗化合物或其药学上可接受的盐或酯的有效量，从而调节淀粉样聚集物的聚集。其中，R1和R2分别独立地是氢原子或取代或未取代的脂肪族或芳香族基团。Z和Q分别独立地是羰基（C═O），硫代羰基（C═S），磺酰基（SO2）或亚砜基（S═O）基团。“k”和“m”均为0或1，当k为1时，R1不是氢原子，当m为1时，R2不是氢原子。在一种实施例中，k或m中至少有一个必须等于1。“p”和“s”分别独立地是正整数，选取这些正整数以便在维持治疗化合物的活性的同时，不会阻止治疗化合物对预期靶位点的生物分布。T是一个连接基团，而Y是一个公式为-A X的基团，其中A是生理pH下的阴离子基团，而X是一个阳离子基团。
• Methods and Compositions for Treating Amyloid-Related Diseases
  申请人：KONG Xianqi

  公开号：US20100190753A1

  公开（公告）日：2010-07-29

  Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease.

  本文描述了用于治疗或预防淀粉样蛋白相关疾病的方法、化合物、药物组合物和试剂盒。
• METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES
  申请人：Kong Xianqi

  公开号：US20100113591A1

  公开（公告）日：2010-05-06

  Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

  本发明涉及用于治疗或预防淀粉样蛋白相关疾病的方法、化合物、制药组合物和试剂盒。